- Home
- NODK vs OBIO Comparison
NODK vs OBIO Comparison
Compare NODK & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- OBIO
- Stock Information
- Founded
- NODK 1946
- OBIO 2017
- Country
- NODK United States
- OBIO United States
- Employees
- NODK N/A
- OBIO N/A
- Industry
- NODK Property-Casualty Insurers
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- NODK Finance
- OBIO Health Care
- Exchange
- NODK Nasdaq
- OBIO Nasdaq
- Market Cap
- NODK 265.4M
- OBIO 118.8M
- IPO Year
- NODK 2017
- OBIO N/A
- Fundamental
- Price
- NODK $13.12
- OBIO $2.89
- Analyst Decision
- NODK
- OBIO Strong Buy
- Analyst Count
- NODK 0
- OBIO 5
- Target Price
- NODK N/A
- OBIO $14.20
- AVG Volume (30 Days)
- NODK 19.7K
- OBIO 392.6K
- Earning Date
- NODK 08-07-2025
- OBIO 08-11-2025
- Dividend Yield
- NODK N/A
- OBIO N/A
- EPS Growth
- NODK N/A
- OBIO N/A
- EPS
- NODK N/A
- OBIO N/A
- Revenue
- NODK $322,139,000.00
- OBIO $2,886,000.00
- Revenue This Year
- NODK N/A
- OBIO $20.47
- Revenue Next Year
- NODK N/A
- OBIO $11.45
- P/E Ratio
- NODK $44.96
- OBIO N/A
- Revenue Growth
- NODK 3.15
- OBIO 30.23
- 52 Week Low
- NODK $12.01
- OBIO $2.37
- 52 Week High
- NODK $17.24
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- NODK 55.46
- OBIO 46.36
- Support Level
- NODK $12.76
- OBIO $2.60
- Resistance Level
- NODK $13.11
- OBIO $2.94
- Average True Range (ATR)
- NODK 0.47
- OBIO 0.25
- MACD
- NODK 0.05
- OBIO -0.04
- Stochastic Oscillator
- NODK 81.25
- OBIO 32.95
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.